• Filling Bone Defects/Voids With Autologous BonoFill-II for Maxillofacial Bone Regeneration

  NCT02842619

  CompletedInterventionalPhase 1Phase 2Updated Dec 10, 2025
• Filling Bone Defects/Voids With Autologous BonoFill For Maxillofacial Bone Regeneration

  NCT02153268

  CompletedInterventionalPhase 1Phase 2Updated Jan 12, 2017
• Efficacy and Safety of SurgiFill™in Patients With Femur or Tibia Fracture

  NCT07518836

  TerminatedInterventionalNot ApplicableUpdated Apr 9, 2026
• Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing

  NCT01842477

  CompletedInterventionalPhase 2Updated Jun 4, 2026
• Study on Safety and Performance of AdvanCore Bone Void Filler

  NCT06736457

  RecruitingInterventionalNot ApplicableUpdated May 31, 2025
• Long-term Safety and Effectiveness of AUGMENT® Bone Graft Compared to Autologous Bone Graft

  NCT02879149

  Unknown statusObservationalUpdated Mar 27, 2018

ClinicalTrials.gov ID

NCT03024008

Lead Sponsor

BonusBio Group LtdINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 1Phase 2

Enrollment

40Estimated

Last Update Posted

Dec 10, 2025Actual

Start Date

Jul 27, 2017Actual

Primary Completion Date

Mar 2027Estimated

Completion Date

Jun 2027Estimated

Official Title

A Multicenter Study to Evaluate the Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II

Brief Summary

The purpose of this clinical study is to evaluate the safety and the efficacy of BonoFill-II as an autologous bone-regenerating graft in the reconstruction of deficient bone in two clinical indications:

1. Long and short bone extra-articular comminuted fracture
2. Long and short bones extra and intra articular defect /Gap or non-union, incapable of self-regeneration

Detailed Description

Primary Endpoint:

Safety: to establish that the transplantation of BonoFill-II into bone defect/gap is safe under the following conditions:

• No treatment-related appearance of heterotrophic bone ossification
• No excessive bone formation at the transplantation sites
• No abnormalities in the treated sites

Efficacy: to establish that the transplantation of BonoFill-II into bone defect/gap is effective under the following conditions:

• Bone continuity, measured radiographically by CT at 6 and 12 months.
• Weight-bearing ability, assessed at 6 and 12 months.

• Bone Fracture

• BonoFill-II

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Long and short bones extra articular comminuted fracture or
• Long and short bones extra and intra articular defect/gap or non union, incapable of self-regeneration

Exclusion Criteria:

• Age is under 18 or above 80
• A simple fracture manageable by one definitive treatment
• Pregnant or lactating women
• Patients with active infection that is in question and needs osteogenic treatment.
• More than 3 previous failed interventions at the surgical site
• History of advanced congestive heart failure or active acute myocardial infarction (AMI), renal failure (estimated GFR of <30 ml/min/1.73 m2 at screening), or hepatic disease (hepatic insufficiency classified as Child-Pugh B or C)
• Diabetic subjects (HbA1c > 8)
• Subject treated currently with systemic steroids.
• Subjects with known autoimmune diseases, such as Addison's disease, Celiac disease - sprue (gluten-sensitive enteropathy), Dermatomyositis, Graves disease, Hashimoto's thyroiditis, Multiple sclerosis, Myasthenia gravis, Pernicious anemia, Reactive arthritis, Rheumatoid arthritis, Sjogren syndrome, Systemic lupus erythematosus.
• Subjects diagnosed with osteoporosis
• Chronic severe PVD (Peripheral Vascular Disease) subjects
• Post major vascular operation in the treated limb/s and above the surgical site (with or without Gore-Tex grafting)
• Subjects that have a known scar healing problem (keloid formation).
• Subjects treated with Bisphosphonate drugs
• Oncology patient or subjects who received chemotherapy or radiotherapy treatment in the past 12 months
• Immunocompromised condition from any reason, at screening
• Subjects participating in another clinical trial 30 days prior to and during the study period.
• Drug addicts and psychiatric patients patients incapable of giving consent.
• Subjects with a known history of any significant medical disorder, which in the investigator's judgment contraindicates the subject's participation
• Subjects with any known allergy for local/general anesthesia
• Positive serology for either HIV, hepatitis B or hepatitis C
• Abnormal clinically significant laboratory test and findings, as per the investigator's judgment

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

BonusBio Group LtdINDUSTRY

yanivy@hy.health.gov.il972-4-7744738